Mitsubishi UFJ Asset Management Co. Ltd. Makes New $829,000 Investment in AngioDynamics, Inc. $ANGO

Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 63,729 shares of the medical instruments supplier’s stock, valued at approximately $829,000. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.15% of AngioDynamics at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. D.A. Davidson & CO. purchased a new position in AngioDynamics in the fourth quarter worth $1,751,000. Weber Capital Management LLC ADV acquired a new stake in AngioDynamics in the fourth quarter valued at $17,978,000. Bastion Asset Management Inc. boosted its position in shares of AngioDynamics by 17.4% during the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after purchasing an additional 194,822 shares in the last quarter. Armistice Capital LLC grew its stake in shares of AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after purchasing an additional 64,000 shares during the period. Finally, Royce & Associates LP grew its stake in shares of AngioDynamics by 27.3% during the 4th quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier’s stock worth $16,274,000 after purchasing an additional 272,091 shares during the period. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Trading Down 0.4%

Shares of NASDAQ ANGO opened at $15.75 on Friday. The stock has a market cap of $650.95 million, a price-to-earnings ratio of -18.10 and a beta of 0.33. AngioDynamics, Inc. has a 52 week low of $9.06 and a 52 week high of $16.29. The company’s 50-day moving average price is $13.96 and its 200 day moving average price is $12.05.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts expect that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ANGO shares. Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. HC Wainwright increased their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Canaccord Genuity Group lifted their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and an average target price of $19.50.

Insider Buying and Selling at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.00% of the stock is currently owned by company insiders.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.